- Home
- SA vs AUPH Comparison
SA vs AUPH Comparison
Compare SA & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SA
- AUPH
- Stock Information
- Founded
- SA 1979
- AUPH 1993
- Country
- SA Canada
- AUPH Canada
- Employees
- SA N/A
- AUPH N/A
- Industry
- SA Precious Metals
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- SA Basic Materials
- AUPH Health Care
- Exchange
- SA Nasdaq
- AUPH Nasdaq
- Market Cap
- SA 1.0B
- AUPH 1.1B
- IPO Year
- SA N/A
- AUPH 1999
- Fundamental
- Price
- SA $15.15
- AUPH $7.49
- Analyst Decision
- SA
- AUPH Strong Buy
- Analyst Count
- SA 0
- AUPH 2
- Target Price
- SA N/A
- AUPH $11.50
- AVG Volume (30 Days)
- SA 820.2K
- AUPH 1.5M
- Earning Date
- SA 08-12-2025
- AUPH 07-31-2025
- Dividend Yield
- SA N/A
- AUPH N/A
- EPS Growth
- SA N/A
- AUPH N/A
- EPS
- SA N/A
- AUPH 0.27
- Revenue
- SA N/A
- AUPH $247,295,000.00
- Revenue This Year
- SA N/A
- AUPH $12.15
- Revenue Next Year
- SA N/A
- AUPH $18.31
- P/E Ratio
- SA N/A
- AUPH $28.12
- Revenue Growth
- SA N/A
- AUPH 29.20
- 52 Week Low
- SA $9.40
- AUPH $5.20
- 52 Week High
- SA $20.55
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- SA 66.53
- AUPH 37.76
- Support Level
- SA $14.00
- AUPH $7.71
- Resistance Level
- SA $14.66
- AUPH $8.86
- Average True Range (ATR)
- SA 0.46
- AUPH 0.34
- MACD
- SA -0.05
- AUPH -0.04
- Stochastic Oscillator
- SA 92.42
- AUPH 13.02
About SA Seabridge Gold Inc. (Canada)
Seabridge Gold Inc is a development stage company involved in the exploration, and development of gold properties sited in North America. The company's principal projects include the Kerr-Sulphurets-Mitchell property located in British Columbia, the Courageous Lake property located in the Northwest Territories, and Iksut Property located in northwestern British Columbia, and the 3 Aces Project in southeast Yukon. The company has various other mineral resource projects throughout North America.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.